Using Trabectedin for Advanced Mesenchymal Chondrosarcoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II clinical study investigates the effectiveness of trabectedin in patients aged 16 and older who have progressive, advanced mesenchymal chondrosarcoma (MCS) with a specific genetic marker (HEY1-NCOA2 fusion). The study is multicenter and uncontrolled, focusing on patients who have previously undergone anthracycline-based chemotherapy. Participants must have measurable disease and evidence of progression within the last six months. The goal is to assess the activity of trabectedin in this specific patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 16 years old
2. Histological centrally confirmed diagnosis of skeletal or extra-skeletal MCS with the documented presence of HEY1-NCOA2 fusion
3. Locally advanced disease and/or metastatic disease
4. Measurable or evaluable disease with RECIST v1.1
5. Evidence of progression by RECIST v1.1 during the 6 months before study entry
6. Patients must be pre-treated with at least one prior chemotherapy treatment containing anthracyclines for the advanced phase of disease and with a maximum of 3 lines
7. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2
8. Adequate bone marrow function
9. Adequate organ function
10. Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation each cycle of chemotherapy.
11. Cardiac ejection fraction ≥50% as measured by echocardiogram
12. No history of arterial and/or venous thromboembolic event within the previous 12 months
13. The patient or legal representative must be able to read and understand the informed consent form and must have been willing to give written informed consent and any locally required authorisation before any study-specific procedures, including screening evaluations, sampling, and analyses.
14. Any other factors, that, at judgment of investigator, could affect the safety of the patients according to the available trabectedin safety data

Exclusion Criteria:

1. Other primary malignancy with \<5 years clinically assessed disease free interval, except basal cell skin cancer, cervical carcinoma in situ or other neoplasm judged to entail a low risk of relapse
2. Previous treatment with radiation therapy within 14 days of first day of study drug dosing, or patients who have not recovered from adverse events due to agents previously administered
3. Previous radiotherapy to 25% of the bone marrow
4. Major surgery within 2 weeks prior to study entry
5. Participation in another clinical study with an investigational product, which last dose was taken less than 4 weeks prior to the start of the treatment.
6. Persistent toxicities (≥ grade 2) with the exception of alopecia, caused by previous anticancer therapies.
7. Pregnancy or breast feeding
8. Grade III/IV cardiac problems as defined by the New York Heart Association Criteria
9. Medical history of arterial thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), or pulmonary embolism within 6 months prior to the initiation of study treatment
10. Known brain metastasis
11. Known chronic liver disease (i.e. chronic active hepatitis and cirrhosis)
12. Known diagnosis oh human deficiency virus (HIV) infection
13. Active or chronic hepatitis B or C requiring treatment with antiviral therapy
14. Medical history of hemorrhage or a bleeding event ≥ Grade 3 within 4 weeks prior to the initiation of study treatment
15. Evidence of any other serious or unstable illness, or medical, psychological, or social condition, that could jeopardize the safety of the subject and/or his/her compliance with study procedures, or may interfere with the subject's participation in the study or evaluation of the study results
16. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation of the study drugs
17. Expected non-compliance to medical regimens

Where it's running

• Nuovo Ospedale di Prato
  Prato, Firenze, Italy Recruiting
• Fondazione del Piemonte per l'Oncologia IRCC Candiolo
  Candiolo, Torino, Italy Recruiting
• Istituto Ortopedico Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors
  Bologna, Italy Recruiting
• Fondazione IRCSS Istituto Nazionale dei Tumori
  Milan, Italy Recruiting
• Ospedale Giaccone
  Palermo, Italy Recruiting
• Istituti Fisioterapici Ospitalieri - Ospedale Regina Elena
  Roma, Italy Recruiting

Study contacts

• Principal investigator: Silvia Stacchiotti, MD — Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
• Study coordinator: Silvia Stacchiotti, MD
• Email: silvia.stacchiotti@istitutotumori.mi.it
• Phone: 39022390

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lurbinectedin plus irinotecan for advanced desmoplastic small round cell tumor

  This study will try lurbinectedin combined with irinotecan in people 15 and older whose desmoplastic small round cell tumor has come back or spread after anthracycline chemotherapy.

  Recruiting at 6 sites Phase 2 Italian Sarcoma Group · Candiolo, Torino and 10 other locations · NCT07328425

• Observational study of localized angiosarcoma

  This study is trying to find the best ways to treat localized angiosarcoma by looking at how patients are managed across different hospitals in Italy.

  Recruiting at 12 sites Italian Sarcoma Group · Rozzano, Milano and 18 other locations · NCT06375941

• Observational study of localized osteosarcoma characteristics and treatments

  This study is looking at the characteristics and treatments of people with localized osteosarcoma to see how well current therapies work and to help improve future care.

  Recruiting at 15 sites Italian Sarcoma Group · Aviano, Pordenone and 15 other locations · NCT04890067

• Observational study on Ewing's sarcoma of the bone

  This study is collecting information from patients with Ewing's sarcoma to learn more about the disease and improve treatment options.

  Recruiting at 17 sites Italian Sarcoma Group · Rozzano, MI and 18 other locations · NCT04845893

• Observational study on breast sarcoma characteristics and outcomes

  This study looks at the characteristics and treatment outcomes of patients with breast sarcoma to help improve care for this rare type of tumor.

  Recruiting Italian Sarcoma Group · Bologna, BO and 13 other locations · NCT04749446

• Evaluating Trabectedin for Advanced Leiomyosarcoma

  This study is testing if a drug called Trabectedin can help people with advanced leiomyosarcoma feel better and live longer compared to another treatment called Gemcitabine.

  Recruiting at 15 sites Phase 2 Italian Sarcoma Group · Bologna, BO and 16 other locations · NCT04383119

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.